Celltrion USA’s adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost

Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) Branded and unbranded versions of Celltrion USA’s adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ — Celltrion USA announced today that…